Biotech Foundations: MMRF Partners with Biotech to Speed Cancer Therapies R&D
By Catherine Shaffer
Tuesday, March 29, 2011
Not satisfied with merely providing early stage research support to fight cancer, the Multiple Myeloma Research Foundation has an "end-to-end" strategy for fostering drug development at every stage. The MMRF, headquartered in Norwalk, Conn., has served as midwife to four breakthrough therapies for multiple myeloma: Velcade, Thalomid, Revlimid and Doxil.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.